Understanding the Development of NCCN Guidelines for High Risk Breast, Ovarian, Pancreatic & Prostate Cancer

Description
In this presentation, Leigha Senter, a current member of the NCCN Guideline Committee for Genetic/Familial High-Risk Assessment for Breast, Ovarian, Pancreatic, and Prostate cancers will review the process by which these guidelines are written and reviewed. Attendees will learn how evidence is categorized and considered and how varied feedback is considered.

Level of Instruction
Intermediate - Refresher course; some basic knowledge of subject recommended

Learning Objectives

  1. Describe the process by which NCCN guidelines are developed for the Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Cancers.
  2. Examine the levels of evidence utilized in the NCCN guidelines.
  3. Evaluate the complexities of having multiple guidelines that include genetics-related information.
Course summary
Available credit: 
  • 0.10 NSGC CEU
  • 1.00 PACE Contact Hour
Course opens: 
04/02/2025
Course expires: 
04/02/2027
Cost:
$0.00

Presenter: Leigha Senter, MS, CGC

Cancer Genetic Counselor and Clinical Professor at The Ohio State University’s James Cancer Hospital and Solove Research Institute

Leigha Senter is a cancer genetic counselor and Clinical Professor at The Ohio State University’s James Cancer Hospital and Solove Research Institute. Currently serving as Interim Director of the Division of Human Genetics, Leigha has more than two decades of research experience in hereditary cancers with a primary focus in BRCA gene-related projects with more than 100 peer reviewed publications. She is currently a member of the NCCN Guideline Committee for Genetic/Familial High-Risk Assessment for Breast, Ovarian, Pancreatic, and Prostate cancers. She’s on the board of trustees for the Association of Cancer Care Centers, an advisory board member for FORCE and past member of the NSGC board of directors.

 

Moderator: Rachel Bluebond, MMSc, CGC

Oncology Genomic Science Liaison at Ambry Genetics

Rachel Bluebond joined Ambry in 2020 as the Oncology Genomic Science Liaison for the South-Central Region.  In her current role she serves as a clinical liaison for the field team to educate health care providers and key opinion leaders on genetic testing and genomic medicine. Rachel previously worked as a clinical oncology genetic counselor at the University of Texas MD Anderson Cancer Center in Houston, Texas for 7 years and has worked with PWNHealth providing telehealth genetic counseling for 4 years. Rachel has been involved in graduate education at the UT MD Anderson UT Houston School of Biomedical Sciences. She is a member of the National Society of Genetic Counselors and the chair of the Billing Workgroup of the Access and Service Delivery Committee. Rachel received her Master of Medical Science degree in Human Genetics and Genetic Counseling from Emory University and is certified by the American Board of Genetic Counseling

Educational Independence and Disclosure Policy

EducateNext is committed to providing independent, objective, and evidence-based educational content. None of the individuals in control of this content—including our planners, reviewers, and approval faculty—have any financial relationships with ineligible companies to disclose. For all educational sessions, speaker-specific disclosures regarding any potential conflicts of interest are required and will always be shared directly with learners at the beginning of their respective presentations.

Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Programs.

 

Available Credit

  • 0.10 NSGC CEU
  • 1.00 PACE Contact Hour

Price

Cost:
$0.00
Please login or register to take this course.

By registering for and taking this activity, you agree to submit your information to Ambry Genetics, who will use it to communicate with you regarding EducateNext educational activities. Ambry may also use this information to inform you of their other services such as upcoming educational activities, product updates, and other future events. You can opt out of such communications at any time. Ambry will always handle your information in line with their Privacy Policy (https://www.ambrygen.com/legal/privacy-policy).